Skip to main content
. 2013 Apr 17;3:91. doi: 10.3389/fonc.2013.00091

Figure 4.

Figure 4

Total number of co-localized TRF2/TERRA foci. Experimental groups consisted of: control (DMSO) and DNA-PK inhibitor (NU7026); control (mock) and hnRNP A1 depleted (siRNA). (A) In MCF-10A, statistically significant increases in co-localization of TERRA at telomeres (TRF2) were observed for both NU7026 and siRNA treatments (*p < 0.05). (B) In MCF-7, no statistically significant differences in co-localization of TERRA at telomeres (TRF2) were observed for either NU7026 or siRNA treatment (p > 0.05). Data are ± SEM for n = 40 TERRA positive cells.